Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. (UNCY): 2 pipeline candidates · ~27 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
27.1 months
D/E 0.71 · 0% dilution
Lead: BLA Filed
2 candidates
N/A
N/A
A transparent, data-derived signal for Unicycive Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$195.6M
Cash
$37.4M
Quarterly Burn
$6.2M
Runway
27.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| oxylanthanum carbonate | BLA Filed |
| uni-494 | Phase 1 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$44.9M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,622,860 | $10.7M |
| millennium management llc | 1,399,348 | $9.2M |
| great point partners llc | 796,558 | $5.2M |
| susquehanna international group, llp | 598,319 | $3.9M |
| citadel advisors llc | 344,741 | $2.3M |
| geode capital management, llc | 203,744 | $1.3M |
| morgan stanley | 188,182 | $1.2M |
| jane street group, llc | 156,143 | $1.0M |
| marshall wace, llp | 154,938 | $1.0M |
| dauntless investment group, llc | 147,087 | $968K |
Showing top 10 of 46 institutional holders of Unicycive Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Unicycive Therapeutics, Inc.'s pipeline?
Unicycive Therapeutics, Inc. (UNCY) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Unicycive Therapeutics, Inc.'s lead drug candidate?
Unicycive Therapeutics, Inc.'s most advanced tracked candidate is oxylanthanum carbonate (BLA Filed) for hyperphosphatemia in CKD patients on dialysis.
What is Unicycive Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Unicycive Therapeutics, Inc. has approximately 27.1 months of cash runway.
What is Unicycive Therapeutics, Inc.'s market capitalization?
Unicycive Therapeutics, Inc.'s market capitalization is approximately $195.6M.
Who is the CEO of Unicycive Therapeutics, Inc.?
Dr. Shalabh K. Gupta M.D., MPA is the chief executive officer of Unicycive Therapeutics, Inc. (UNCY).
Get the full picture on Unicycive Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.